Chartwell Investment Partners LLC cut its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 79.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,899 shares of the medical instruments supplier's stock after selling 11,080 shares during the quarter. Chartwell Investment Partners LLC's holdings in West Pharmaceutical Services were worth $870,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in WST. Kayne Anderson Rudnick Investment Management LLC boosted its position in West Pharmaceutical Services by 6.8% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier's stock worth $195,556,000 after acquiring an additional 37,702 shares during the period. Sei Investments Co. boosted its holdings in shares of West Pharmaceutical Services by 12.7% during the second quarter. Sei Investments Co. now owns 401,026 shares of the medical instruments supplier's stock worth $132,095,000 after purchasing an additional 45,208 shares during the period. Envestnet Asset Management Inc. grew its position in West Pharmaceutical Services by 9.8% during the second quarter. Envestnet Asset Management Inc. now owns 301,339 shares of the medical instruments supplier's stock valued at $99,258,000 after purchasing an additional 26,947 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in West Pharmaceutical Services by 11.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 288,639 shares of the medical instruments supplier's stock valued at $95,075,000 after buying an additional 30,253 shares during the period. Finally, Epoch Investment Partners Inc. lifted its position in West Pharmaceutical Services by 3.5% in the 2nd quarter. Epoch Investment Partners Inc. now owns 269,675 shares of the medical instruments supplier's stock worth $88,828,000 after buying an additional 9,156 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at West Pharmaceutical Services
In related news, VP Charles Witherspoon sold 703 shares of the company's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total value of $218,211.20. Following the completion of the sale, the vice president now directly owns 1,253 shares in the company, valued at approximately $388,931.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.53% of the company's stock.
West Pharmaceutical Services Stock Up 5.1 %
Shares of NYSE:WST traded up $16.64 during trading on Wednesday, reaching $344.12. 970,363 shares of the company traded hands, compared to its average volume of 571,903. The firm has a fifty day simple moving average of $304.87 and a 200 day simple moving average of $316.60. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The firm has a market cap of $24.92 billion, a P/E ratio of 51.06, a price-to-earnings-growth ratio of 24.78 and a beta of 1.00.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.35. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The firm had revenue of $746.90 million during the quarter, compared to analysts' expectations of $709.62 million. During the same quarter last year, the firm earned $2.16 earnings per share. The business's revenue for the quarter was down .1% on a year-over-year basis. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.66 earnings per share for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 0.24%. The ex-dividend date is Wednesday, November 13th. This is a positive change from West Pharmaceutical Services's previous quarterly dividend of $0.20. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 11.87%.
West Pharmaceutical Services Profile
(
Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
